A BAYESIAN ADAPTIVE RANDOMIZED PHASE II TRIAL OF BEVACIZUMAB VERSUS BEVACIZUMAB PLUS VORINOSTAT IN ADULTS WITH RECURRENT GLIOBLASTOMA FINAL RESULTS

被引：0

作者：

Puduvalli, Vinay ^{[1
]}

Wu, Jing ^{[2
]}

Yuan, Ying ^{[3
]}

Armstrong, Terri ^{[2
]}

Wu, Jimin ^{[3
]}

Giglio, Pierre ^{[4
]}

Xu, Jihong ^{[1
]}

Colman, Howard ^{[5
,6
]}

Walbert, Tobias ^{[7
]}

Raizer, Jeffrey ^{[8
]}

Groves, Morris ^{[9
]}

Iwamoto, Fabio ^{[10
]}

Tran, David ^{[11
]}

Avgeropoulos, Nicholas ^{[12
]}

Paleologos, Nina ^{[13
]}

Fink, Karen ^{[14
]}

Peereboom, David ^{[15
]}

Chamberlain, Marc ^{[16
]}

Merrell, Ryan ^{[17
]}

Penas-Prado, Marta ^{[3
]}

Yung, W. K. Alfred ^{[18
]}

Gilbert, Mark ^{[2
]}

机构：

[1] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA

[2] NCI, Neurooncol Branch, CCR, NIH, Bethesda, MD 20892 USA

[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[4] Ohio State Univ, Columbus, OH 43210 USA

[5] Univ Utah, Dept Neurosurg, Huntsman Canc Inst, Salt Lake City, UT USA

[6] Univ Utah, Clin Neurosci Ctr, Salt Lake City, UT USA

[7] Henry Ford Hosp, Detroit, MI 48202 USA

[8] Northwestern Univ, Chicago, IL 60611 USA

[9] Texas Oncol Austin Brain Tumor Ctr, Austin, TX USA

[10] Columbia Univ, New York, NY USA

[11] Univ Florida, Gainesville, FL USA

[12] Univ Florida, Orlando, FL USA

[13] Advocate Hlth Care, Chicago, IL USA

[14] Baylor Univ, Dallas, TX USA

[15] Cleveland Clin, Cleveland, OH 44106 USA

[16] Univ Washington, Seattle, WA 98195 USA

[17] Northshore Univ, Evanston, IL USA

[18] Univ Texas MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA

来源：

NEURO-ONCOLOGY | 2018年 / 20卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ACTR-13

引用

页码：13 / 13

页数：1

共 50 条

[41] A RANDOMIZED PHASE II STUDY ON BEVACIZUMAB VERSUS BEVACIZUMAB PLUS LOMUSTINE VERSUS LOMUSTINE SINGLE AGENTIN RECURRENT GLIOBLA STOMA: THE DUTCH BELOB STUDY
Taal, Walter
Oosterkamp, H.
Walenkamp, Annemieke
Beerenpoot, Lucas
Hanse, Monique
Buter, Jan
Honkoop, Aafke
Boerman, Dolf
de Vos, Filip
Jansen, R.
van der Berkmortel, Franchette
Brandsma, Dieta
Enting, Roelien
Kros, Johan
Bromberg, Jacoline
van Heuvel, Irene
Smits, Marion
van der Holt, Ronnie
Vernhout, Rene
van den Bent, Martin
NEURO-ONCOLOGY, 2013, 15 : 83 - 84
[42] Onartuzumab plus bevacizumab versus placebo plus bevacizumab in recurrent glioblastoma (GBM): HGF and MGMT biomarker data
Cloughesy, Timothy Francis
Finocchiaro, Gaetano
Belda, Cristobal
Recht, Lawrence
Brandes, Alba Ariela
Pineda, Estela
Mikkelsen, Tom
Chinot, Olivier L.
Balana, Carmen
Macdonald, David R.
Westphal, Manfred
Hopkins, Kirsten
Weller, Michael
Liu, Bo
Bruey, Jean-Marie
Verret, Wendy
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[43] Second-line treatment of bevacizumab plus lomustine versus bevacizumab plus irinotecan in patients with recurrent glioblastoma
Simoes, J.
Tavares, N. T.
Borges, C.
Meireles, S.
Fernandes, C.
Costa, A.
Caeiro, C.
Damasceno, M.
ANNALS OF ONCOLOGY, 2018, 29
[44] Phase II study of pembrolizumab or pembrolizumab plus bevacizumab for recurrent glioblastoma (rGBM) patients
Reardon, David A.
Nayak, Lakshmi
Peters, Katherine B.
Clarke, Jennifer Leigh
Jordan, Justin T.
De Groot, John Frederick
Nghiemphu, Phioanh Leia
Kaley, Thomas Joseph
Colman, Howard
Gaffey, Sarah C.
Caruso, Victoria
Debruyne, Myriam Bednarek
Bhavsar, Chinmay
Molinaro, Annette M.
Smith, Timothy
Severgnini, Mariano
Wen, Patrick Y.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[45] PHASE II AND BIOMARKER STUDY OF PEMBROLIZUMAB OR PEMBROLIZUMAB PLUS BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA PATIENTS
Reardon, David
Molinaro, Annette
Peters, Katherine
Clarke, Jennifer
Jordan, Justin
de Groot, John
Nghiemphu, Phioanh
Kaley, Thomas
Colman, Howard
McCluskey, Christine
Smith, Timothy
Cote, David
Severgnini, Mariano
Yearley, Jennifer
Zhao, Qing
Blumenschein, Wendy
Duda, Gabriel
Muzikansky, Alona
Jain, Rakesh
Wen, Patrick
Nayak, Lakshmi
NEURO-ONCOLOGY, 2020, 22 : 40 - 40
[46] PHASE II STUDY OF BEVACIZUMAB PLUS ETOPOSIDE AMONG RECURRENT MALIGNANT GLIOMA PATIENTS: FINAL STUDY RESULTS
Reardon, David A.
Desjardins, Annick
Vredenburgh, James J.
Gururangan, Sridharan
Peters, Katherine B.
Norfleet, Julie A.
Friedman, Allan H.
Friedman, Henry S.
NEURO-ONCOLOGY, 2009, 11 (06) : 905 - 905
[47] Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab na⟨ve, recurrent glioblastoma
Reardon, David A.
Desjardins, Annick
Peters, Katherine B.
Gururangan, Sridharan
Sampson, John H.
McLendon, Roger E.
Herndon, James E., II
Bulusu, Anuradha
Threatt, Stevie
Friedman, Allan H.
Vredenburgh, James J.
Friedman, Henry S.
JOURNAL OF NEURO-ONCOLOGY, 2012, 107 (01) : 155 - 164
[48] Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma
David A. Reardon
Annick Desjardins
Katherine B. Peters
Sridharan Gururangan
John H. Sampson
Roger E. McLendon
James E. Herndon
Anuradha Bulusu
Stevie Threatt
Allan H. Friedman
James J. Vredenburgh
Henry S. Friedman
Journal of Neuro-Oncology, 2012, 107 : 155 - 164
[49] THE RANDOMIZED PHASE II ARTE TRIAL: BEVACIZUMAB PLUS HYPOFRACTIONATED RADIOTHERAPY VERSUS RADIOTHERAPY ALONE IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
Weller, Michael
Tabatabai, Ghazaleh
Roelcke, Ulrich
Hottinger, Andreas
Joerger, Francisca
Schmid, Andrea
Plasswilm, Ludwig
Schrimpf, Daniel
Mancao, Christoph
Capper, David
Conen, Katrin
Hundsberger, Thomas
Caparrotti, Francesca
von Moos, Roger
Riklin, Christian
Felsberg, Joerg
Roth, Patrick
Jones, David
Pfister, Stefan M.
Rushing, Elisabeth Jane
Abrey, Lauren
Reifenberger, Guido
Held, Leonhard
von Deimling, Andreas
Ochsenbein, Adrian
Wirsching, Hans-Georg
NEURO-ONCOLOGY, 2017, 19 : 2 - 2
[50] Phase II trial of capecitabine, oxaliplatin plus bevacizumab followed by bevacizumab plus erlotinib: XELOBER trial
Munoz, A.
Salut, A.
Pericay, C.
Garcia, C.
Roca, J.
Duenas, R.
Rivera, F.
Alonso, V.
Alonso, M.
Falco, E.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

← 1 2 3 4 5 →